Spruce Biosciences, Inc. (SPRB)
NASDAQ: SPRB · Real-Time Price · USD
0.483
-0.007 (-1.41%)
Nov 21, 2024, 1:14 PM EST - Market open
Spruce Biosciences Stock Forecast
SPRB's stock price has decreased by -63.7% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Spruce Biosciences stock have an average target of 2.50, with a low estimate of 2.00 and a high estimate of 3.00. The average target predicts an increase of 417.49% from the current stock price of 0.48.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for SPRB stock from 7 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 5 | 5 | 5 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Reiterates $2 | Hold | Reiterates | $2 | +313.99% | Nov 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Aug 19, 2024 |
| RBC Capital | RBC Capital | Hold Reiterates $2 | Hold | Reiterates | $2 | +313.99% | Aug 13, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $4 → $3 | Buy | Maintains | $4 → $3 | +520.99% | Jun 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jun 5, 2024 |
Financial Forecast
Revenue This Year
6.34M
from 10.09M
Decreased by -37.13%
Revenue Next Year
1.77M
from 6.34M
Decreased by -72.13%
EPS This Year
-1.01
from -1.24
EPS Next Year
-0.95
from -1.01
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 9.8M | 5.5M | 12.1M | ||
| Avg | 6.3M | 1.8M | 5.9M | ||
| Low | 3.5M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.6% | -13.9% | 583.0% | ||
| Avg | -37.1% | -72.1% | 231.7% | ||
| Low | -65.0% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.93 | -0.88 | -0.58 | ||
| Avg | -1.01 | -0.95 | -0.83 | ||
| Low | -1.06 | -1.00 | -1.27 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.